AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04502992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Committment Therapy
Description: Acceptance and Commitment Therapy (ACT) is a mindfulness-based therapy that focuses on enabling individuals to accept what is out of their control, and to commit to valued actions that enrich their lives (Vowles \& McCracken, 2008). By emphasizing acceptance instead of avoidance, ACT differs from many other forms of cognitive behavioral therapy. ACT has been shown to be efficacious in terms of clinical outcomes, adherence to treatment, and retention. ACT aims to increase psychological flexibility, and has been associated with improved health outcomes prior randomized controlled clinical trials, including three systematic reviews specific to CP. Psychological flexibility is defined as an individual's ability to recognize and adapt to various demands; shift mindsets or behavioral responses when these strategies compromise personal or social functioning; and maintain balance among important life domains.
Study NCT02712970 — intervention group
Intervention type: PROCEDURE
Intervention: pit-picking technique
Description: midline pits were excised removing a minimal amount of tissue (with a margin of skin of \<1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
Study NCT02712970 — intervention group
Intervention type: PROCEDURE
Intervention: Bascom Cleft Lift
Description: The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
Study NCT01096680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 20 mg
Description: Single oral dose of 20 mg
Study NCT01096680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 50 mg
Description: Single oral dose of 50 mg
Study NCT01096680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 70 mg
Description: Single oral dose of 70 mg
Study NCT01096680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Single oral dose of 250 mg
Study NCT01096680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study NCT00497055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study NCT00497055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Aripiprazole gel caps.
Study NCT02696174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMI
Description: A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
Study NCT01483599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (5 mg)
Description: Subcutaneous (SC) injections
Study NCT01483599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (15 mg)
Description: SC injections
Study NCT01483599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (50 mg)
Description: SC injections
Study NCT01483599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (100 mg)
Description: SC injections
Study NCT01483599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CNTO 1959 (100 mg)
Description: SC injections
Study NCT01483599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (200 mg)
Description: SC injections
Study NCT01483599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: SC injections
Study NCT01483599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injections
Study NCT03634813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Blood Pressure Monitor
Description: High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)
Study NCT03634813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT00673374 — intervention group
Intervention type: DEVICE
Intervention: radio-opaque adhesive skin markers
Description: The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
Study NCT02712970 — intervention group
Intervention type: PROCEDURE
Intervention: Rhomboid excision with the Limberg Flap
Description: The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
Study NCT02712970 — intervention group
Intervention type: PROCEDURE
Intervention: Other flap techniques
Description: Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
Study NCT01089296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Individually customized physiotherapy
Description: Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.
Study NCT02953509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT02953509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
Study NCT01118572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM177
Description: oral
Study NCT01118572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etodolac
Description: oral
Study NCT01118572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01680952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A) TEST
Description: 1. Extended Release Tacrolimus (Advagraf®)~   ① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~   ② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~2. Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level.
Study NCT01680952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A) TEST
Description: 1. Extended Release Tacrolimus (Advagraf®)~   ① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~   ② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~2. Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level.
Study NCT01680952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B) CONTROL
Description: 1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid
Study NCT01680952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B) CONTROL
Description: 1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid
Study NCT01358240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate Foam 1%
Description: Econazole Nitrate Foam 1% applied once a day for 4 weeks
Study NCT02953509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
Study NCT02953509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
Study NCT01358240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam applied once a day for 4 week
Study NCT01358240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Econazole Nitrate Cream 1%
Description: Econazole Nitrate Foam 1% applied once a day for 4 weeks
Study NCT01358240 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream applied once a day for 4 weeks
Study NCT00629148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine and Capecitabine
Description: Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
Study NCT00629148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine and Capecitabine
Description: Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
Study NCT02182154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 ES
Study NCT02483325 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Allogeneic transplant conditioning
Description: Allogeneic transplant
Study NCT00817505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral tablet
Study NCT00817505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral suspension
Study NCT03679819 — intervention group
Intervention type: DEVICE
Intervention: HR-TRUS
Description: Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
Study NCT02148016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LSCs and amniotic membrane (Modified Technique)
Description: Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched.
Study NCT02148016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane only (Traditional Technique)
Description: Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
Study NCT02148016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRK, LSCs, and amniotic membrane (Modified Technique)
Description: Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched.
Study NCT02148016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK only (Traditional Technique)
Description: PRK alone will be performed.
Study NCT02148016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study NCT02148016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Study NCT02148016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Limbal stem cells (LSCs)
Study NCT04652518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-100
Description: oral administration
Study NCT04652518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LYT-100
Description: oral administration
Study NCT04652518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT01100190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUVANCE Facial Rejuvenation System
Description: The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
Study NCT03271099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigator
Description: Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
Study NCT01602679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral micronized progesterone suspension
Description: oral micronized progesterone (100 mg p.o.) suspension
Study NCT01602679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral micronized progesterone suspension
Description: oral micronized progesterone (100 mg p.o.) suspension
Study NCT01602679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study NCT01602679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study NCT02018770 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
Study NCT02018770 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo phototherapy
Description: The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
Study NCT00270621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHP Night time ENuresis Intervention
Description: Urine alarm/evidence-based psychological Intervention
Study NCT04615221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Specimens
Description: Specimens (blood, biopsy, cervical smear, vaginal swab)
Study NCT03124498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK Cell
Description: Autologous cytokine-induced killer (CIK) cell
Study NCT02623959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (IV)
Description: Fentanyl 50 mcg given by vein prior to catheter draining.
Study NCT02623959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (IV)
Description: Fentanyl 50 mcg given by vein prior to catheter draining.
Study NCT02933528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS Topical product
Description: once daily for 28 days
Study NCT02623959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
Study NCT02623959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
Study NCT02623959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Calls
Description: After the IPC is removed, participant is called one time each month by study staff to check on their status.
Study NCT02623959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: After the IPC is removed, participant is called one time each month by study staff to check on their status.
Study NCT03294538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Estradiol Vaginal Cream USP, 0.01%
Description: Vaginal cream, generic formulation of the brand product.
Study NCT03294538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace® Vaginal Cream USP, 0.01%
Description: Vaginal cream, brand product.
Study NCT03294538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Vaginal Cream
Description: Vaginal cream, placebo. Has no active ingredient
Study NCT00100165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice a day for 4 weeks
Study NCT00100165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg
Description: 3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks
Study NCT00100165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
Description: 3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks
Study NCT01368003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA9090
Description: 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
Study NCT01368003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA9090 with Dutasteride
Description: Dutasteride 3.5 mg orally per day STA9090 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
Study NCT03565549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mnemonic
Description: A mnemonic used as a memory aid
Study NCT03565549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCHR rule
Description: A list of the CCHR items
Study NCT00325403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral treprostinil (UT-15C) Sustained Release Tablets
Description: Sustained release oral tablet, twice daily
Study NCT00325403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet twice daily
Study NCT04511390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transparent, reusable respirator
Description: A novel respirator with dual N95 filter cartridges
Study NCT05153122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseGuard
Description: SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals.
Study NCT01575678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: blinded capsule 2-4 mg/day, oral use, for 4 weeks
Study NCT01575678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: blinded capsule 1/day, oral use, for 4 weeks
Study NCT04258670 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (>20,000 Mf/mL)
Study NCT00326079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: implantation of 1 Glaukos iStent versus 2 Glaukos iStents
Study NCT01689753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEGO connector®